In last trading session, Oncocyte Corporation (NASDAQ:OCX) saw 0.33 million shares changing hands with its beta currently measuring 0.94. Company’s recent per share price level of $2.43 trading at $0.0 or -0.21% at ring of the bell on the day assigns it a market valuation of $40.91M. That closing price of OCX’s stock is at a discount of -72.43% from its 52-week high price of $4.19 and is indicating a premium of 17.7% from its 52-week low price of $2.00. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.12 million shares which gives us an average trading volume of 39.59K if we extend that period to 3-months.
For Oncocyte Corporation (OCX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.33. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Oncocyte Corporation (NASDAQ:OCX) trade information
Upright in the red during last session for losing -0.21%, in the last five days OCX remained trading in the red while hitting it’s week-highest on Friday, 11/22/24 when the stock touched $2.43 price level, adding 13.21% to its value on the day. Oncocyte Corporation’s shares saw a change of -2.80% in year-to-date performance and have moved -8.99% in past 5-day. Oncocyte Corporation (NASDAQ:OCX) showed a performance of -19.54% in past 30-days. Number of shares sold short was 0.23 million shares which calculate 3.8 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 10 to the stock, which implies a rise of 75.7% to its current value. Analysts have been projecting 4.25 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -74.9% in reaching the projected high whereas dropping to the targeted low would mean a loss of -74.9% for stock’s current value.
Oncocyte Corporation (OCX) estimates and forecasts
This year revenue growth is estimated to fall -66.73% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 101.67k for the same. And 2 analysts are in estimates of company making revenue of 158.55k in the next quarter. Company posted 314k and 176k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 14.72% during past 5 years.
Oncocyte Corporation (NASDAQ:OCX)’s Major holders
Insiders are in possession of 15.96% of company’s total shares while institution are holding 50.58 percent of that, with stock having share float percentage of 60.19%. Investors also watch the number of corporate investors in a company very closely, which is 50.58% institutions for Oncocyte Corporation that are currently holding shares of the company. AWM INVESTMENT COMPANY, INC. is the top institutional holder at OCX for having 1.1 million shares of worth $3.24 million. And as of 2024-06-30, it was holding 13.2766 of the company’s outstanding shares.
The second largest institutional holder is DEFENDER CAPITAL, LLC., which was holding about 55220.0 shares on 2024-06-30. The number of shares represents firm’s hold over 0.6682 of outstanding shares, having a total worth of $0.16 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 153.99 shares of worth $0.38 million or 0.91% of the total outstanding shares. The later fund manager was in possession of 85.0 shares on Jun 30, 2024 , making its stake of worth around $0.21 million in the company or a holder of 0.50% of company’s stock.
